Bet on Rising Price-to-Earnings With 5 Top Stocks

by Sanghamitra Saha Published on July 10,2020

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

• BLRX Quick QuoteBLRXNegative Net Change
• AVGR Quick QuoteAVGRNegative Net Change
• PTI Quick QuotePTIPositive Net Change
• VIVE Quick QuoteVIVENo Net Change
• VCNX Quick QuoteVCNXPositive Net Change

• earnings

Aclaris (ACRS) Surges: Stock Moves 5.4% Higher

by Zacks Equity Research Published on July 08,2020

Aclaris (ACRS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

• BLRX Quick QuoteBLRXNegative Net Change
• ACRS Quick QuoteACRSPositive Net Change

• medical

Pacira (PCRX) Provides Preliminary Results for Second Quarter

by Zacks Equity Research Published on July 07,2020

Pacira (PCRX) reports preliminary results for the second quarter of 2020. The company's product sales are hurt by the COVID-19 pandemic. The stock fell in pre-market trading.

• BLRX Quick QuoteBLRXNegative Net Change
• PCRX Quick QuotePCRXPositive Net Change
• ATXI Quick QuoteATXIPositive Net Change
• AMRX Quick QuoteAMRXPositive Net Change

• medical

Acceleron (XLRN) in Focus: Stock Moves 5.3% Higher

by Zacks Equity Research Published on July 06,2020

Acceleron (XLRN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

• BLRX Quick QuoteBLRXNegative Net Change
• XLRN Quick QuoteXLRNPositive Net Change

Zogenix (ZGNX) in Focus: Stock Moves 7.6% Higher

by Zacks Equity Research Published on July 02,2020

Zogenix (ZGNX) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

• BLRX Quick QuoteBLRXNegative Net Change
• ZGNX Quick QuoteZGNXNegative Net Change

• medical

Corcept Begins Enrollment in Phase III Pancreatic Cancer Study

by Zacks Equity Research Published on July 01,2020

Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.

• MRK Quick QuoteMRKPositive Net Change
• BMY Quick QuoteBMYNegative Net Change
• BLRX Quick QuoteBLRXNegative Net Change
• CORT Quick QuoteCORTPositive Net Change

• medical

CytoDyn Signs MOU With NIH of Mexico for Coronavirus Study

by Zacks Equity Research Published on June 30,2020

CytoDyn's (CYDY) shares rise more than 20% as it inks an MOU with NIH of Mexico to conduct a COVID-19 study on leronlimab.

• BLRX Quick QuoteBLRXNegative Net Change
• CYDY Quick QuoteCYDYNegative Net Change
• OPHLF Quick QuoteOPHLFNo Net Change
• AMRX Quick QuoteAMRXPositive Net Change

• pharmaceuticals

GlycoMimetics (GLYC) in Focus: Stock Moves 8.1% Higher

by Zacks Equity Research Published on June 30,2020

GlycoMimetics (GLYC) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

• BLRX Quick QuoteBLRXNegative Net Change
• GLYC Quick QuoteGLYCPositive Net Change

• medical

Onconova Initiates Phase I/IIa Study on Lung Cancer Candidate

by Zacks Equity Research Published on June 23,2020

Onconova (ONTX) starts investigator-initiated phase I/IIa study of oral rigosertib plus Bristol-Myers Squibb's Opdivo in advanced metastatic KRAS-mutated lung adenocarcinoma.

• BMY Quick QuoteBMYNegative Net Change
• BLRX Quick QuoteBLRXNegative Net Change
• ONTX Quick QuoteONTXNo Net Change
• AMRX Quick QuoteAMRXPositive Net Change

• pharmaceuticals

Jazz's Aggressive Lung Cancer Drug Zepzelca Gets FDA Approval

by Zacks Equity Research Published on June 16,2020

FDA's accelerated approval to Jazz's (JAZZ) Zepzelca as a monotherapy for metastatic small cell lung cancer patients set to boost the company's oncology portfolio.

• JAZZ Quick QuoteJAZZPositive Net Change
• BLRX Quick QuoteBLRXNegative Net Change
• BLCM Quick QuoteBLCMPositive Net Change
• ATNM Quick QuoteATNMNegative Net Change

• pharmaceuticals

Top Ranked Momentum Stocks to Buy for May 29th

by Zacks Equity Research Published on May 29,2020

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 29th.

• NTNX Quick QuoteNTNXPositive Net Change
• GSV Quick QuoteGSVPositive Net Change
• BLRX Quick QuoteBLRXNegative Net Change
• AXU Quick QuoteAXUPositive Net Change

• gold
• medical

BioLineRx Concludes Recruitment in Pancreatic Cancer Study

by Zacks Equity Research Published on January 23,2020

BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.

• MRK Quick QuoteMRKPositive Net Change
• RHHBY Quick QuoteRHHBYPositive Net Change
• BLRX Quick QuoteBLRXNegative Net Change
• KALV Quick QuoteKALVNegative Net Change

• medical

BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU

by Zacks Equity Research Published on January 15,2020

The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.

• MRK Quick QuoteMRKPositive Net Change
• RHHBY Quick QuoteRHHBYPositive Net Change
• KPTI Quick QuoteKPTINegative Net Change
• BLRX Quick QuoteBLRXNegative Net Change

• medical

BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors

by Zacks Equity Research Published on September 26,2019

BioLineRx (BLRX) starts dosing the first patient in the part 2 of the phase I/IIa study evaluating AGI-134 for solid tumors.

• RHHBY Quick QuoteRHHBYPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• FGEN Quick QuoteFGENPositive Net Change
• BLRX Quick QuoteBLRXNegative Net Change

• pharmaceuticals

Tenet Healthcare (THC) Q2 Earnings: What's in the Cards?

by Zacks Equity Research Published on August 02,2019

Tenet Healthcare's (THC) second-quarter earnings are likely to suffer due to lower revenues.

• ADVM Quick QuoteADVMNegative Net Change
• BLRX Quick QuoteBLRXNegative Net Change
• THC Quick QuoteTHCPositive Net Change
• ACER Quick QuoteACERNo Net Change

• medical

BioCryst Down Despite Hereditary Angioedema Study Meets Goal

by Zacks Equity Research Published on May 22,2019

BioCryst's (BCRX) phase III study on BCX7353 for the prevention of hereditary angioedema attacks meets the primary endpoint for both doses (110mg/150 mg). Shares depreciate despite this upside.

• BCRX Quick QuoteBCRXNegative Net Change
• JAZZ Quick QuoteJAZZPositive Net Change
• BLRX Quick QuoteBLRXNegative Net Change
• ASRT Quick QuoteASRTPositive Net Change

• medical

BioLineRx (BLRX) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research Published on May 17,2019

BioLineRx (BLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

• BLRX Quick QuoteBLRXNegative Net Change

• earnings-estimates
• earnings-estimates-revisions
• earnings-outlook
• energy
• rating-upgrade
• stock-price-movement
• zacks-consensus-estimate
• zacks-rank

Can The Uptrend Continue for BioLineRx (BLRX)?

by Zacks Equity Research Published on October 08,2018

Investors certainly have to be happy with BioLineRx Ltd. (BLRX) and its short term performance.

• BLRX Quick QuoteBLRXNegative Net Change

• biotechs

BioLineRx (BLRX) in Focus: Stock Moves 7.5% Higher

by Zacks Equity Research Published on October 05,2018

BioLineRx (BLRX) shares rose nearly 8% in the last trading session, amid huge volumes.

• BLRX Quick QuoteBLRXNegative Net Change
• BSTC Quick QuoteBSTCPositive Net Change

BioLineRx Stock Up on Stake Increase in Lead Cancer Program

by Zacks Equity Research Published on October 04,2018

BioLineRx (BLRX) signs an agreement with Biokine Therapeutics to raise its economic interest in its lead oncology platform, BL-8040, by 20%.

• MRK Quick QuoteMRKPositive Net Change
• RHHBY Quick QuoteRHHBYPositive Net Change
• UTHR Quick QuoteUTHRPositive Net Change
• BLRX Quick QuoteBLRXNegative Net Change

Portola's (PTLA) Lymphoma Candidate Gets Orphan Drug Status

by Zacks Equity Research Published on September 26,2018

Portola's (PTLA) oral Syk/JAK inhibitor, cerdulatinib, secures an orphan drug designation from the FDA for treating patients with peripheral T-cell lymphoma.

• PCRX Quick QuotePCRXPositive Net Change
• BLRX Quick QuoteBLRXNegative Net Change
• BSTC Quick QuoteBSTCPositive Net Change
• PTLA Quick QuotePTLAPositive Net Change

BioLineRx (BLRX) Continue to Surge Higher?

by Zacks Equity Research Published on September 21,2018

As of late, it has definitely been a great time to be an investor in BioLineRx Ltd. (BLRX).

• BLRX Quick QuoteBLRXNegative Net Change

CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA

by Zacks Equity Research Published on July 19,2018

CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.

• INCY Quick QuoteINCYPositive Net Change
• CTIC Quick QuoteCTICPositive Net Change
• BLRX Quick QuoteBLRXNegative Net Change
• ACRX Quick QuoteACRXPositive Net Change

VIVUS' PAH Candidate Data Positive in Early Stage Study

by Zacks Equity Research Published on July 11,2018

VIVUS' (VVUS) pipeline candidate, VI-0106, shows positive activity in a preliminary analysis of phase I study in patients with pulmonary arterial hypertension.

• VVUS Quick QuoteVVUSPositive Net Change
• BLRX Quick QuoteBLRXNegative Net Change
• ACRX Quick QuoteACRXPositive Net Change
• CLGN Quick QuoteCLGNNegative Net Change

Aclaris' Alopecia Candidate Gets Fast Track Designation

by Zacks Equity Research Published on July 10,2018

The FDA grants fast track status to Aclaris' (ACRS) JAK-inhibitor, ATI-502, for the treatment of alopecia areata.

• BLRX Quick QuoteBLRXNegative Net Change
• ACRX Quick QuoteACRXPositive Net Change
• ACRS Quick QuoteACRSPositive Net Change
• CLGN Quick QuoteCLGNNegative Net Change